Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EBITDA: 2009-2024

Historic EBITDA for RedHill Biopharma (RDHL) over the last 16 years, with Dec 2024 value amounting to -$14.0 million.

  • RedHill Biopharma's EBITDA rose 291.87% to $101.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$52.9 million, marking a year-over-year increase of 70.93%. This contributed to the annual value of -$14.0 million for FY2024, which is 158.64% down from last year.
  • Latest data reveals that RedHill Biopharma reported EBITDA of -$14.0 million as of FY2024, which was down 158.64% from $23.9 million recorded in FY2023.
  • RedHill Biopharma's EBITDA's 5-year high stood at $63.7 million during FY2020, with a 5-year trough of -$97.7 million in FY2021.
  • Moreover, its 3-year median value for EBITDA was -$14.0 million (2024), whereas its average is -$20.6 million.
  • Per our database at Business Quant, RedHill Biopharma's EBITDA tumbled by 253.48% in 2021 and then spiked by 133.37% in 2023.
  • RedHill Biopharma's EBITDA (Yearly) stood at $63.7 million in 2020, then crashed by 253.48% to -$97.7 million in 2021, then increased by 26.68% to -$71.7 million in 2022, then skyrocketed by 133.37% to $23.9 million in 2023, then plummeted by 158.64% to -$14.0 million in 2024.